top of page
1/2
Pioneering Novel
Life-Saving Medicines
for Cardiomyopathies
Our Mission
At Nuevocor, our mission is to transform the treatment of untreatable cardiomyopathies by embracing a mechanobiology-centered approach.
These devastating conditions pose a significant global healthcare challenge, affecting individuals at a relatively young age and can rapidly lead to heart failure. Presently, the only recourse for these patients is a costly and often elusive cardiac transplant.
To address this challenge, we are building global collaborations with leading experts and institutions, accelerating the development of innovative solutions that offer these patients viable alternatives and improved outcomes.
About Us
With global operations across the United States, Europe and Singapore, Nuevocor focuses on treating heart conditions known as cardiomyopathies by addressing their underlying mechanical defects.
Nuevocor’s lead program, NVC-001, is a novel genetic medicine that treats patients suffering from LMNA-related dilated cardiomyopathy, an aggressive, rare disease with no available targeted treatments.
News
8 October 2026
Nuevocor Doses First Patient in SUNBEAM-LMNA Phase 1/2 Trial and Receives FDA Fast Track Designation for NVC-001 in LMNA Dilated Cardiomyopathy
SINGAPORE, PARIS and PHILADELPHIA, Oct. 8, 2026 /PRNewswire/ -- Nuevocor, a clinical-stage biotechnology company pioneering mechanobiology-targeted therapies designed to address the root causes of life-threatening cardiomyopathies, today announced that the first patient has been dosed in SUNBEAM-LMNA, its first-in-human Phase 1/2 clinical trial evaluating lead asset NVC-001 in adults with LMNA dilated cardiomyopathy (LMNA DCM).
28 April 2026
Nuevocor Appoints Dr. Monica Shah as Chief Medical Officer
SINGAPORE, PARIS and PHILADELPHIA, April 28, 2026 /PRNewswire/ -- Nuevocor, a clinical-stage biotechnology company developing novel therapies for patients suffering from life-threatening cardiomyopathies, today announced the appointment of Monica Shah, MD, FACC, as Chief Medical Officer.
bottom of page